The mammalian target of rapamycin (mTOR) inhibitor everolimus given with the aromatase inhibitor exemestane markedly boosts progression-free survival (PFS) in post-menopausal women with advanced breast cancer compared with hormonal therapy alone, according to updated results of the phase III...